Scarica l'app Stockscreener
8.94
21.30%
1.57
Pre-mercato:
8.94
Precedente Chiudi:
$7.37
Aprire:
$6.72
Volume 24 ore:
2.75M
Relative Volume:
8.26
Capitalizzazione di mercato:
$163.69M
Reddito:
$137.27M
Utile/perdita netta:
$-123.57M
Rapporto P/E:
-0.8115
EPS:
-11.016
Flusso di cassa netto:
$-102.89M
1 W Prestazione:
+46.80%
1M Prestazione:
+9.09%
6M Prestazione:
+122.39%
1 anno Prestazione:
+1.74%
Intervallo 1D:
$6.72
$9.9399
Intervallo di 1 settimana:
$5.90
$9.9399
Portata 52W:
$3.51
$10.38
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Nome
Karyopharm Therapeutics Inc
Settore
Industria
Telefono
617-658-0600
Indirizzo
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
8.94 | 134.95M | 137.27M | -123.57M | -102.89M | -11.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-10-13 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | Ripresa | H.C. Wainwright | Buy |
| 2023-01-19 | Iniziato | Piper Sandler | Overweight |
| 2022-11-04 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Iniziato | Morgan Stanley | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-07-23 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-05 | Reiterato | Robert W. Baird | Outperform |
| 2019-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Reiterato | BofA/Merrill | Underperform |
| 2019-02-27 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Iniziato | B. Riley FBR | Buy |
| 2018-11-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2018-05-24 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-04-02 | Ripresa | Leerink Partners | Outperform |
| 2017-11-15 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2016-09-08 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2016-08-18 | Iniziato | H.C. Wainwright | Buy |
| 2016-06-28 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Karyopharm Therapeutics Inc Borsa (KPTI) Ultime notizie
Karyopharm Therapeutics Inc Shares Rise After Q4 2025 Results - AlphaStreet News
Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Financial Challenges - GuruFocus
Karyopharm reports fourth quarter and full year 2025 financial results and highlights recent company progress - marketscreener.com
Karyopharm Q4 2025 slides: Revenue growth amid pivotal myelofibrosis readout preparations - Investing.com
Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlig - GuruFocus
Karyopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results, Misses Expectations By $3.45 EPS - MarketBeat
Page not foundAirwhon - MarketBeat
Karyopharm (KPTI) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Karyopharm sees 11.8% revenue rise in Q4 2025 - Investing.com India
Karyopharm Q4 2025 slides: Revenue growth amid pivotal myelofibrosis readout preparations By Investing.com - Investing.com India
KPTI: Q4 revenue up, operating loss improved, pivotal phase 3 data in myelofibrosis due soon - TradingView
Karyopharm Therapeutics: Fourth Quarter Earnings Overview - Bitget
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Karyopharm Therapeutics Inc (NASDAQ:KPTI) Reports Q4 Revenue Miss and Wider Loss, Stock Falls in Pre-Market - ChartMill
KARYOPHARM THERAPEUTICS ($KPTI) Releases Q4 2025 Earnings - Quiver Quantitative
Karyopharm Therapeutics: Q4 Earnings Snapshot - WWLTV.com
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress - PR Newswire
Karyopharm Reports 2025 Financials and 2026 Outlook - Intellectia AI
Uncovering Potential: Karyopharm Therapeutics's Earnings Preview - Benzinga
Investment Report: Can Karyopharm Therapeutics Inc disrupt its industry2025 Earnings Surprises & Low Risk High Reward Ideas - baoquankhu1.vn
Stock Market Recap: Can Karyopharm Therapeutics Inc disrupt its industryTrade Performance Summary & Risk Managed Investment Entry Signals - baoquankhu1.vn
Karyopharm Therapeutics (KPTI) Expected to Announce Earnings on Thursday - MarketBeat
Karyopharm Therapeutics (KPRX): Tiny Cancer Stock, Massive Drama – Is It Worth Your Money? - AD HOC NEWS
Cantor Fitzgerald Initiates Coverage on KPTI with Overweight Rat - GuruFocus
Cantor Fitzgerald initiates Karyopharm stock with Overweight rating By Investing.com - Investing.com South Africa
Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - Karyopharm
Cancer drug maker Karyopharm to detail 2025 results in Feb. 12 call - Stock Titan
Cantor Fitzgerald Initiates Coverage on Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
Cantor Fitzgerald initiates Karyopharm stock with Overweight rating - Investing.com India
Karyopharm Therapeutics reports inducement grants under Nasdaq Listing Rule - marketscreener.com
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
FOMO Trade: How sensitive is Karyopharm Therapeutics Inc to inflationJuly 2025 Highlights & High Accuracy Investment Signals - baoquankhu1.vn
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Up 110.2% in January - Defense World
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update - MarketBeat
Abate, Karyopharm Therapeutics CAO, sells $351 in stock By Investing.com - Investing.com UK
Abate, Karyopharm Therapeutics CAO, sells $351 in stock - Investing.com
Myelofibrosis Clinical Trials Outlook: Competitive Intelligence, Regulatory Progress, Emerging Therapies, Mechanisms of Action, and Administration Pathways – DelveInsight - Barchart.com
Portfolio Update: mơ công an bắt xeQuarterly Earnings Report & Proven Capital Preservation Methods - baoquankhu1.vn
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below 50-Day Moving AverageHere's What Happened - MarketBeat
Can Karyopharm Unlock Xpovio's Growth In 2026 With Pivotal Myelofibrosis Data Ahead? - RTTNews
How New Price Targets Are Shaping The Story For Karyopharm Therapeutics (KPTI) - Yahoo Finance
Abate, Karyopharm Therapeutics CAO, sells $1.6k in stock By Investing.com - Investing.com UK
Abate, Karyopharm Therapeutics CAO, sells $1.6k in stock - Investing.com
RBC Raises Price Target on Karyopharm Therapeutics to $23 From $19, Keeps Outperform Rating - marketscreener.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aug Spikes: Can Karyopharm Therapeutics Inc disrupt its industryDividend Hike & Verified Entry Point Signals - baoquankhu1.vn
Chart Watch: Will Karyopharm Therapeutics Inc outperform its industry peersJuly 2025 Intraday Action & Technical Pattern Alert System - baoquankhu1.vn
Options Flow: Will Karyopharm Therapeutics Inc 25K0 stock rise with strong economyWeekly Risk Summary & Safe Entry Zone Tips - Bộ Nội Vụ
Layoff Watch: What margin trends mean for Karyopharm Therapeutics Inc stockWeekly Stock Analysis & Accurate Intraday Trading Signals - Bộ Nội Vụ
Karyopharm Therapeutics Inc Azioni (KPTI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):